Priavoid uses mirror-image-phage-display-selection and various optimization technologies to develop compounds composed exclusively of D-enantiomeric (mirror image) amino acids. Our all-D-peptide development platform enables the generation of lead compounds for any given target, especially for CNS disorders. In contrast to natural peptides consisting of L-amino acids, this new class of drug substances is resistant to proteases, permeate the blood-brain-barrier effectively, display very low immunogenicity and degradation profiles in vivo and are therefore suitable for oral drug administration, for example as a tablet.


Pre-clinical and clinical trials are pursued at Priavoid for the development of drugs for treatment of neurodegenerative diseases.


The drug pipeline of Priavoid is composed of 6 compounds in development with 5 CNS diseases

Cookie Preference

Please select an option. You can find more information about the consequences of your choice at Help.

Select an option to continue

Your selection was saved!



To continue, you must make a cookie selection. Below is an explanation of the different options and their meaning.

  • Accept all cookies:
    All cookies such as tracking and analytics cookies.
  • Accept first-party cookies only:
    Only cookies from this website.
  • Reject all cookies:
    No cookies except for those necessary for technical reasons are set.

You can change your cookie setting here anytime: Privacy Policy. Legal Notice